Novel siRNA Therapy Shows Promise in Treating Liver Fat Disease
Experimental CIDEB siRNA treatment normalizes liver fat levels in early-stage clinical trial participants.
1Phase I Trial Success
A phase I trial involving 40 patients demonstrated that the novel siRNA therapy ALN-CIDEB successfully normalizes liver fat in individuals with MASLD. After 36 weeks, 62% of treated participants achieved normal liver fat levels below 5%. These results, presented at the annual Liver Meeting, highlight a potential breakthrough for metabolic liver conditions.
2Significant Fat Reduction
The study revealed that 93% of participants receiving the CIDEB siRNA treatment achieved a 30% relative reduction in liver fat. In contrast, only 10% of the placebo group reached this milestone. These findings suggest the therapy effectively targets the biological mechanisms controlling fat droplet size within human liver cells.
3Liver Enzyme Improvements
Serum alanine aminotransferase levels, a key marker for liver health, dropped by 32% among treated patients by week 12. By week 36, the 600-mg dosage group experienced a 36.5% reduction in ALT levels. Meanwhile, the placebo group saw a 6.6% increase, underscoring the drug's potential to improve overall liver function.
4Dosing Frequency Potential
The sustained efficacy observed beyond the six-month mark suggests that ALN-CIDEB could eventually be administered as infrequently as twice per year. This long-acting therapeutic profile offers a significant advantage over daily lifestyle management. Researchers believe this dosing schedule could improve patient adherence and long-term clinical outcomes for those managing chronic liver disease.
5Mechanism of Action
The therapy functions by targeting mRNA coded by the CIDEB gene, which regulates the size of fat droplets in liver cells. Genetic studies indicate that individuals with loss-of-function mutations in this gene naturally face lower risks of cirrhosis and MASH. By mimicking this effect, the siRNA treatment addresses the root cause of fat accumulation.
6Study Limitations Noted
Lead researcher Jörg Tübel cautioned that this is a first-in-human study with limited data. The trial was not powered for statistical inference, and participants generally lacked advanced fibrosis or elevated baseline enzymes. Consequently, the findings may not fully generalize to patients suffering from more severe forms of metabolic dysfunction-associated steatohepatitis.
7Safety Profile Observations
Treatment-emergent adverse event rates remained comparable between the treatment and placebo groups, at 87% and 90% respectively. While 10% of treated patients experienced drug-related adverse events, none occurred in the placebo group. Common side effects included upper respiratory tract infections, which were reported at similar frequencies across both study cohorts.
8Future Clinical Development
Given the positive phase I outcomes, the CIDEB siRNA program is advancing rapidly through the clinical pipeline. The drug has already moved into a phase II trial specifically targeting MASH and a phase III trial for broader MASLD applications. These upcoming studies will provide more robust data regarding long-term efficacy and safety.
Original article: MedPage Today — Novel siRNA Therapy Shows Promise in Treating Liver Fat Disease